NEW YORK (360Dx) – Medicortex Finland announced on Tuesday a deal with Pro-Lab Diagnostics aimed at commercializing Medicortex's brain injury detection kit in Canada and the UK.
Under the terms of the agreement Pro-Lab will shepherd the kit through the regulatory processes in Canada and the UK, as well as be responsible for clinical validation of the kit. Medicortex has granted Pro-Lab exclusive rights to sell the test in Canada and the UK in return for royalties.
The two companies also intend to initiate a development collaboration, the terms of which are still to be determined. Financial and other details of the agreement were not disclosed.
Medicortex's urine-based test is intended for use after a brain injury for the detection of a biomarker discovered and characterized by the Finnish firm. In a statement, it said that upon the development of the test, it plans to develop a drug to impede the progress of brain injuries.
Pro-Lab, headquartered in Ontario, provides immunodiagnostic products and distributes products in the clinical microbiology, molecular biology, and transfusion medicine markets, and others.